Wallis K, Walters J R F, Forbes A
Division of Medicine, Imperial College, Hammersmith Hospital, London, UK.
Aliment Pharmacol Ther. 2007 Feb 15;25(4):365-72. doi: 10.1111/j.1365-2036.2006.03193.x. Epub 2007 Jan 8.
Glucagon-like peptide 2 (GLP-2) is an important peptide growth factor secreted from the human intestine. The trophic properties of GLP-2 are very specific to the gut where it is pivotal in the regulation of mucosal morphology, function and integrity.
This review details the current understanding of the molecular biology of GLP-2, its mechanisms of action and physiological properties. A major focus is the discussion of recent clinical data evaluating the use of GLP-2 as a therapeutic agent.
Relevant articles were identified using Medline searches and from the reference lists of key papers.
In the treatment of short bowel syndrome, GLP-2 has been shown to be highly effective in improving fluid absorption. In Crohn's disease, GLP-2 is superior to placebo in the induction of remission. Early data also suggest that the effects of GLP-2 on bone metabolism can provide a new treatment approach for patients with osteoporosis. In the future, the positive effects of GLP-2 on intestinal barrier function, splanchnic perfusion and mucosal healing could be utilized to expand its therapeutic application to other causes of intestinal injury. However, important safety aspects need to be considered when using this potent growth-promoting agent for a long term.
胰高血糖素样肽2（GLP-2）是一种从人体肠道分泌的重要肽类生长因子。GLP-2的营养特性对肠道具有高度特异性，在调节黏膜形态、功能和完整性方面起着关键作用。
本综述详细阐述了目前对GLP-2分子生物学、作用机制和生理特性的理解。主要重点是讨论评估GLP-2作为治疗药物应用的近期临床数据。
通过医学文献数据库检索以及关键论文的参考文献列表确定相关文章。
在短肠综合征的治疗中，GLP-2已被证明在改善液体吸收方面非常有效。在克罗恩病中，GLP-2在诱导缓解方面优于安慰剂。早期数据还表明，GLP-2对骨代谢的影响可为骨质疏松症患者提供一种新的治疗方法。未来，GLP-2对肠道屏障功能、内脏灌注和黏膜愈合的积极作用可用于将其治疗应用扩展到其他肠道损伤原因。然而，长期使用这种强效生长促进剂时需要考虑重要的安全问题。
